



e-ISSN: 2319-8753 | p-ISSN: 2347-6710

IJRSET

International Journal of Innovative Research in
SCIENCE | ENGINEERING | TECHNOLOGY

INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

Volume 13, Issue 7, July 2024

ISSN INTERNATIONAL
STANDARD
SERIAL
NUMBER
INDIA

Impact Factor: 8.423

 9940 572 462

 6381 907 438

 ijrset@gmail.com

 www.ijrset.com

The Role of Neurotransmitters in Emotional Regulation

Tishya Jain

Student, New Delhi, India

ABSTRACT: This research explores the critical function of neurotransmitters in managing emotions, focusing on serotonin, dopamine, norepinephrine, and gamma-aminobutyric acid (GABA). By examining current studies, it highlights how disruptions in these neurotransmitters lead to emotional conditions like depression, schizophrenia, and anxiety. The investigation delves into the microscopic ways neurotransmitters influence emotions, underscoring their importance in maintaining psychological well-being. Furthermore, it discusses drug therapies targeting neurotransmitter systems and the future of research in this field, emphasizing the potential for personalized treatments and improved outcomes in managing emotional disorders.

KEYWORDS: Neurotransmitters, emotional regulation, psychiatric disorders

I. INTRODUCTION

Neurotransmitters act as chemical messengers in the brain, carrying messages from one nerve cell to another and playing a crucial role in various bodily and mental functions. The ability to regulate emotions, which involves monitoring, evaluating, and modifying emotional responses, is essential for maintaining mental health and overall well-being (Jiang et al., 2022). Understanding how neurotransmitters function in emotional regulation provides insights into the mechanisms underlying mood disorders, anxiety, and other emotional issues.

This study aims to investigate the complex relationship between neurotransmitters and emotional regulation. By analyzing key neurotransmitters such as serotonin, dopamine, norepinephrine, and GABA, we can understand how their levels and activities impact emotions. For instance, serotonin is commonly associated with mood stability, while dopamine is linked to reward systems. Norepinephrine affects arousal and alertness, and GABA is involved in reducing neuronal activity and anxiety.

This investigation identifies potential treatment options for managing emotional instability and related mental health issues (Gasmi et al., 2022). By understanding the role of neurotransmitters in emotional regulation, this study aims to establish a foundation for better therapies and approaches, ultimately improving the well-being of individuals facing emotional and psychological difficulties.

II. RATIONALE AND OBJECTIVE

The rationale behind this study is to explore the role of neurotransmitters in emotional regulation and identify potential therapeutic approaches for managing emotional instability and associated mental health issues. By understanding the mechanisms underlying neurotransmitter function, this study aims to improve therapeutic strategies and enhance the well-being of individuals with emotional and psychological difficulties (Khan and Mubarik, 2022).

Objectives:

- Identify Key Neurotransmitters in Emotion Regulation:** Outline the primary neurotransmitters responsible for managing emotions, including serotonin, dopamine, norepinephrine, and GABA. Understanding their roles lays the foundation for exploring their impact on emotional conditions.
- Investigate How Neurotransmitters Affect Emotions:** Explore the mechanisms through which neurotransmitters interact with brain pathways to influence emotions. Understanding these processes can reveal how imbalances lead to emotional regulation difficulties and related mental health issues.
- Evaluate Medical Applications of Neurotransmitter Research:** Assess the impact of neurotransmitter

research on developing new therapies for emotional conditions. By identifying potential treatment areas, this study aims to establish a foundation for improved treatments and mental well-being outcomes.

III. METHODOLOGY

This study utilizes a secondary research approach, focusing on an in-depth examination and analysis of existing studies and literature on neurotransmitters and their impact on emotional regulation. The investigation involves systematically collecting information from various scholarly articles, academic publications, and credible digital sources. Key databases such as Google Scholar are used to gather relevant research and publications.

The study method involves identifying and selecting relevant sources and critically analyzing their findings. This approach enables the synthesis of current knowledge on how neurotransmitters like serotonin, dopamine, norepinephrine, and GABA contribute to emotional regulation (Gammon, 2020). The analysis aims to identify trends, connections, and gaps in existing research.

IV. LITERATURE REVIEW

Emotional Regulation and Neurotransmitters:

Neurotransmitters play a crucial role in the brain's ability to manage emotions, and many research efforts have focused on understanding their essential functions in this area (Moroz, Romanova, and Kohn, 2021). Specific neurotransmitters, including serotonin, dopamine, norepinephrine, and GABA, have received significant attention due to their major influence on emotional well-being and mood (Teleanu et al., 2022).

Serotonin

Serotonin, commonly known as the "happy hormone," plays a crucial role in maintaining stable moods and a general sense of emotional well-being. It is produced from the amino acid tryptophan and is primarily found in the digestive system, blood cells, and the brain. Approximately 90% of the body's serotonin is found in the digestive system, where it regulates intestinal movements, while the remaining 10% in the brain affects mood and emotions (Sharma, 2024).

The importance of serotonin in emotional regulation is well-documented. Reduced serotonin levels are strongly linked to major depressive disorder (MDD). Antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs), are often used to treat depression by increasing serotonin levels in the brain. SSRIs are effective in about 60% of individuals with MDD, highlighting the critical role of serotonin in mood regulation.

Dopamine

Dopamine is a vital neurotransmitter primarily associated with the brain's reward and pleasure systems. It is produced in several brain regions, including the substantia nigra and the ventral tegmental area. Dopamine influences motivation, reward perception, and learning through rewards, making it essential for behaviors related to pleasure and satisfaction (Lawn et al., 2023).

The relationship between dopamine and emotional regulation is evident in its role in mental health conditions. Elevated dopamine levels are associated with schizophrenia, a condition characterized by distorted thinking and perceptions. Conversely, reduced dopamine function is linked to Parkinson's disease, often involving depressive symptoms. Imbalances in dopamine signaling can lead to various emotional issues, from decreased motivation to increased anxiety.

Norepinephrine

Norepinephrine, also known as noradrenaline, is crucial for the body's "fight or flight" response. Produced in the adrenal glands and the locus coeruleus in the brainstem, norepinephrine affects arousal, alertness, and stress responses. It prepares the body to respond to stress by increasing heart rate, blood pressure, and glucose levels (Teleanu et al., 2022).

Studies have shown that norepinephrine is closely linked to anxiety and stress-related disorders. Elevated levels of norepinephrine are observed in individuals with post-traumatic stress disorder (PTSD), indicating its role in

maintaining fear memories and heightened arousal (Sharma, 2024). Medications that inhibit norepinephrine reuptake (NRIs) are prescribed for attention deficit hyperactivity disorder (ADHD) and depression, further highlighting its importance in emotional regulation (Singh, Khanna, and Kalra, 2020).

GABA

GABA, the primary inhibitory neurotransmitter in the brain, is essential for reducing neuronal activity and maintaining neuronal stability. It prevents excessive neuronal firing, helping to regulate anxiety and prevent overstimulation that can lead to emotional disorders (Wisłowska- Stanek, Kołosowska, and Maciejak, 2021).

Research underscores GABA's crucial role in anxiety regulation. Individuals with anxiety disorders often exhibit reduced GABA levels, indicating a clear link between GABA dysfunction and heightened anxiety. Benzodiazepines, drugs that enhance GABA function, are commonly used to treat anxiety, with many patients experiencing significant symptom relief (Alexander et al., 2021).

Processes of Neurotransmitter Function:

Research has significantly advanced our understanding of the intricate processes by which neurotransmitters influence emotions. These processes occur at the microscopic level, involving complex interactions among neurotransmitters, receptors, and brain pathways.

Serotonin

Serotonin, primarily produced in the brainstem, is crucial for mood regulation by binding to specific receptors, particularly the 5-HT1A and 5-HT2A receptors, located in key brain regions like the prefrontal cortex and amygdala. When these receptors are activated, they initiate a cascade of intracellular reactions, affecting neuronal response and signal transmission (Pahwa et al., 2021).

For instance, activation of 5-HT1A receptors has been shown to reduce anxiety, highlighting serotonin's role in anxiety regulation (Sharma, 2024).

Dopamine

Dopamine primarily functions by interacting with dopamine receptors in the brain, especially in the limbic system, which is responsible for emotions and motivation. Dopamine-producing neurons in the ventral tegmental area project to various regions, including the nucleus accumbens and the prefrontal cortex (Kane et al., 2021). Activation of dopamine receptors, such as D1 and D2 receptors, modulates synaptic plasticity and neural activity, influencing reward processing and emotional responses. Dysregulation of dopamine signaling is implicated in numerous psychiatric conditions, including addiction and mood disorders.

Norepinephrine

Norepinephrine, released by neurons originating from the locus coeruleus, acts on adrenergic receptors throughout the brain and body. In the central nervous system, it influences arousal, attention, and stress responses by stimulating alpha and beta-adrenergic receptors. By enhancing neuronal excitability and synaptic transmission, norepinephrine prepares the body to respond to threats, supporting the "fight-or-flight" response (Leucht et al., 2020). Imbalances in norepinephrine signaling are associated with various disorders, such as anxiety and PTSD.

GABA

GABA, the primary inhibitory neurotransmitter, exerts its effects by binding to GABA receptors, which come in two main types: GABAA and GABAB. GABAA receptors facilitate fast inhibitory signaling by allowing chloride ions to enter the neuron, leading to hyperpolarization and reduced excitability (Shimomura et al., 2021). This inhibitory effect is crucial for maintaining the balance of neuronal circuits, preventing overstimulation, and regulating emotional responses. Dysregulation of GABAergic signaling is linked to conditions such as anxiety, epilepsy, and mood disorders.

Disruptions in Neurotransmitter and Emotional Disorders:

Disturbances in neurotransmitter levels are often linked to various emotional and mental health issues, highlighting the importance of maintaining neurotransmitter balance for mental well-being (Grant, Flis, and Ryan, 2022). Imbalances in

specific neurotransmitters have been extensively studied in relation to disorders such as depression, schizophrenia, anxiety disorders, and mood swings.

Serotonin and Depression

A deficiency in serotonin is a well-established factor in the pathophysiology of depression. Research indicates that alterations in serotonin synthesis, release, and receptor sensitivity contribute to the development of depressive symptoms (Potkin et al., 2020). According to the World Health Organization (WHO), depression affects over 264 million people worldwide, ranking as a leading cause of disability globally. SSRIs, which increase serotonin levels in the brain, are among the most commonly prescribed treatments for depression and have shown efficacy in alleviating depressive symptoms in many patients, underscoring serotonin's critical role in mood regulation.

Dopamine and Schizophrenia

Elevated dopamine levels have long been associated with the pathogenesis of schizophrenia, a severe mental disorder characterized by hallucinations, delusions, and cognitive impairment. The hyperdopaminergic hypothesis posits that excessive dopamine activity in specific brain regions, such as the mesolimbic pathway, contributes to the positive symptoms of schizophrenia (Abi-Dargham et al., 2022). Antipsychotic medications, which block dopamine receptors, are the primary treatment for schizophrenia and help mitigate psychotic symptoms. The National Institute of Mental Health (NIMH) reports that approximately 1.2% of the U.S. population is affected by schizophrenia, highlighting the significance of dopamine regulation in this disorder.

Norepinephrine and Anxiety Disorders

Disruption in norepinephrine regulation is implicated in the development of anxiety disorders, including generalized anxiety disorder (GAD), panic disorder, and PTSD (Dwyer et al., 2020). Elevated norepinephrine levels are associated with increased arousal and hypervigilance, leading to symptoms such as restlessness, irritability, and heightened alertness. The Anxiety and Depression Association of America (ADAA) states that anxiety disorders affect approximately 40 million adults in the U.S., making them the most prevalent mental health issue (Li et al., 2021). Treatments for anxiety disorders often involve medications that modulate norepinephrine signaling, such as NRIs and beta-blockers, to alleviate anxiety symptoms.

GABA and Mood Swings

A deficiency in GABA is linked to mood swings and the rapid cycling of emotional states, characteristic of conditions like bipolar disorder. Dysregulation of GABAergic signaling interferes with the brain's ability to modulate emotional responses, leading to alternating periods of mania and depression. The NIMH estimates that approximately 4.4% of U.S. adults experience bipolar disorder (Malgaroli, Calderon, and Bonanno, 2021). Mood stabilizers, which enhance GABA activity, are commonly prescribed to manage these symptoms and stabilize mood fluctuations.

Drug Treatments Aimed at Brain Chemical Receptors:

Drug therapies targeting neurotransmitter systems are essential in managing mental health conditions such as depression, schizophrenia, and anxiety. These medications aim to restore neurotransmitter balance and alleviate symptoms associated with neurotransmitter imbalances. Common treatments include SSRIs, antipsychotic medications, and benzodiazepines.

SSRIs

SSRIs are a class of medications commonly used to treat depression and anxiety by inhibiting the reuptake of serotonin in the brain, thereby increasing its availability for neurotransmission. SSRIs are typically the first-line treatment for depression due to their efficacy and favorable side effect profile. According to the NIMH, SSRIs are effective in approximately 60% of individuals with major depressive disorder (MDD). Common SSRIs include fluoxetine, sertraline, and escitalopram (Sharma, 2024).

Antipsychotic Medications

Antipsychotic medications, also known as neuroleptics, are prescribed to manage symptoms of schizophrenia and other psychotic disorders. These drugs primarily target dopamine receptors in the brain to reduce symptoms such as hallucinations and delusions. First-generation antipsychotics primarily block dopamine D2 receptors, while second-generation antipsychotics also interact with serotonin receptors. The National Alliance on Mental Illness (NAMI)

reports that antipsychotic medications are effective in reducing psychotic symptoms in approximately 70% of individuals with schizophrenia (Dwyer et al., 2020). Common antipsychotic medications include risperidone, olanzapine, and quetiapine.

Benzodiazepines

Benzodiazepines enhance the function of GABA, the brain's primary inhibitory neurotransmitter. They are mainly used to manage anxiety disorders such as GAD, panic disorder, and social anxiety disorder. These medications work by increasing GABA activity, resulting in a calming and sedative effect (Sharma, 2024). However, benzodiazepines carry the risk of dependence, tolerance, and withdrawal symptoms with long-term use. The ADAA advises against long-term use of benzodiazepines for anxiety management. Well-known benzodiazepines include alprazolam (Xanax), clonazepam (Klonopin), and lorazepam (Ativan).

Future Directions in Neurotransmitter Research:

Research on neurotransmitters and their role in emotional regulation is continually evolving, with emerging studies exploring new aspects and pathways for understanding and treating emotional disorders. Advances in brain imaging, genetic research, and pharmacological development hold promise for uncovering novel insights and improving therapeutic outcomes.

Neuroimaging Studies

Advanced neuroimaging techniques such as functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) have revolutionized our understanding of neurotransmitter systems in the brain. For example, fMRI studies have revealed distinct patterns of brain activity associated with serotonin and dopamine function, shedding light on their roles in mood regulation and reward processing (Sharma, 2024).

Genetic Studies

Genetic research has significantly enhanced our understanding of neurotransmitter systems and emotional regulation. By examining the entire genome, researchers have identified specific genetic variations associated with neurotransmitter synthesis, metabolism, and receptor function, providing insights into individual differences in emotional experiences and susceptibility to mental health disorders.

Pharmacological Development

The development of novel pharmacological agents targeting neurotransmitter systems offers hope for more effective and precise treatments for mental health disorders. New medications are being developed with improved selectivity and reduced side effects, targeting specific neurotransmitter receptors and pathways implicated in psychiatric conditions. For example, researchers are investigating novel serotonergic and dopaminergic agents for conditions such as depression and schizophrenia (Nemeroff, 2020).

Precision Medicine Approaches

The emerging field of precision medicine aims to tailor treatments to individual patients based on their unique genetic profiles, biomarker signatures, and clinical characteristics (Sharma, 2024). Pharmacogenetic testing can predict an individual's response to specific medications, guiding personalized treatment decisions and improving therapeutic outcomes.

V. CONCLUSION

The future of neurotransmitter research promises significant advancements in our understanding of emotional regulation and the development of more effective treatments for emotional disorders. Advances in neuroimaging and genetic research are opening new avenues for exploring the functions and impacts of neurotransmitters. Additionally, the development of targeted pharmacological agents and the rise of precision medicine approaches hold promise for personalized and effective treatments tailored to individual needs. These advancements offer the potential for improved quality of life and mental health outcomes for individuals facing emotional challenges. The ongoing pursuit of knowledge in neurotransmitter research is poised to transform our understanding of emotional regulation and provide hope for a future with a wide range of effective therapeutic options.

REFERENCES

1. Abdel-Bakky, M.S., Amin, E., Faris, T.M. and Abdellatif, A.A., 2021. Mental depression: Relation to different disease status, newer treatments and its association with COVID-19 pandemic. *Molecular medicine reports*, 24(6), pp.1-17.
2. Abi-Dargham, A., Javitch, J.A., Slifstein, M., Anticevic, A., Calkins, M.E., Cho, Y.T., Fonteneau, C., Gil, R., Girgis, R., Gur, R.E. and Gur, R.C., 2022. Dopamine D1R receptor stimulation as a mechanistic pro-cognitive target for schizophrenia. *Schizophrenia bulletin*, 48(1), pp.199-210.
3. Alexander, R., Aragón, O.R., Bookwala, J., Cherbuin, N., Gatt, J.M., Kahrilas, I.J., Kästner, N., Lawrence, A., Lowe, L., Morrison, R.G. and Mueller, S.C., 2021. The neuroscience of positive emotions and affect: Implications for cultivating happiness and wellbeing. *Neuroscience & Biobehavioral Reviews*, 121, pp.220-249.
4. Conway, M.E., 2020. Alzheimer's disease: targeting the glutamatergic system. *Biogerontology*, 21(3), pp.257-274.
5. da Silva Miguel, R.D., Barros, J.E.B., Junior, G.F.N., da Silva Costa, I.C., Xavier, J.E., dos Santos Oliveira, L., Koike, B.D.V. and de Souza, S.L., 2020. Is there a relationship between hippocampus-dependent memory and 5-HT_{2A} receptors? Insights from a systematic review. *Brazilian Journal of Health Review*, 3(2), pp.2355-2373.
6. Dwyer, J.B., Aftab, A., Radhakrishnan, R., Widge, A., Rodriguez, C.I., Carpenter, L.L., Nemeroff, C.B., McDonald, W.M., Kalin, N.H. and APA Council of Research Task Force on Novel Biomarkers and Treatments, 2020. Hormonal treatments for major depressive disorder: state of the art. *American Journal of Psychiatry*, 177(8), pp.686-705.
7. Dwyer, J.B., Aftab, A., Radhakrishnan, R., Widge, A., Rodriguez, C.I., Carpenter, L.L., Nemeroff, C.B., McDonald, W.M., Kalin, N.H. and APA Council of Research Task Force on Novel Biomarkers and Treatments, 2020. Hormonal treatments for major depressive disorder: state of the art. *American Journal of Psychiatry*, 177(8), pp.686-705.
8. Gammon, E., 2020. Affective neuroscience, emotional regulation, and international relations. *International Theory*, 12(2), pp.189-219.
9. Gasmí, A., Nasreen, A., Menzel, A., Gasmí Benahmed, A., Pivina, L., Noor, S., Peana, M., Chirumbolo, S. and Bjørklund, G., 2022. Neurotransmitters regulation and food intake: The role of dietary sources in neurotransmission. *Molecules*, 28(1), p.210.
10. Grant, C.E., Flis, A.L. and Ryan, B.M., 2022. Understanding the role of dopamine in cancer: past, present and future. *Carcinogenesis*, 43(6), pp.517-527.
11. Jiang, Y., Zou, D., Li, Y., Gu, S., Dong, J., Ma, X., Xu, S., Wang, F. and Huang, J.H., 2022. Monoamine neurotransmitters control basic emotions and affect major depressive disorders. *Pharmaceuticals*, 15(10), p.1203.
12. Kane, J.M., McEvoy, J.P., Correll, C.U. and Llorca, P.M., 2021. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. *CNS drugs*, pp.1-17.
13. Khan, A. and Mubarak, M.S., 2022. Measuring the role of neurotransmitters in investment decision: A proposed constructs. *International Journal of Finance & Economics*, 27(1), pp.258-274.
14. Lawn, T., Howard, M.A., Turkheimer, F., Misić, B., Deco, G., Martins, D. and Dipasquale, O., 2023. From neurotransmitters to networks: Transcending organisational hierarchies with molecular-informed functional imaging. *Neuroscience & Biobehavioral Reviews*, p.105193.
15. Leucht, S., Crippa, A., Sifakis, S., Patel, M.X., Orsini, N. and Davis, J.M., 2020. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. *American Journal of Psychiatry*, 177(4), pp.342-353.
16. Li, Z., Ruan, M., Chen, J. and Fang, Y., 2021. Major depressive disorder: advances in neuroscience research and translational applications. *Neuroscience bulletin*, 37, pp.863-880.
17. Li, Z., Ruan, M., Chen, J. and Fang, Y., 2021. Major depressive disorder: advances in neuroscience research and translational applications. *Neuroscience bulletin*, 37, pp.863-880.
18. Malgaroli, M., Calderon, A. and Bonanno, G.A., 2021. Networks of major depressive disorder: A systematic review. *Clinical Psychology Review*, 85, p.102000.
19. Marotta, R., Risoleo, M.C., Messina, G., Parisi, L., Carotenuto, M., Vetri, L. and Roccella, M., 2020. The neurochemistry of autism. *Brain sciences*, 10(3), p.163.
20. Moroz, L.L., Romanova, D.Y. and Kohn, A.B., 2021. Neural versus alternative integrative systems: molecular

- insights into origins of neurotransmitters. *Philosophical Transactions of the Royal Society B*, 376(1821), p.20190762.
21. Nemeroff, C.B., 2020. The state of our understanding of the pathophysiology and optimal treatment of depression: glass half full or half empty?. *American Journal of Psychiatry*, 177(8), pp.671-685.
 22. Pahwa, M., Sleem, A., Elsayed, O.H., Good, M.E. and El-Mallakh, R.S., 2021. New antipsychotic medications in the last decade. *Current Psychiatry Reports*, 23(12), p.87.
 23. Potkin, S.G., Kane, J.M., Correll, C.U., Lindenmayer, J.P., Agid, O., Marder, S.R., Olfson, M. and Howes, O.D., 2020. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. *NPJ schizophrenia*, 6(1), p.1.
 24. Sharma, I., 2024. The Role of Neurotransmitters in Emotional Regulation. *International Journal of Indian Psychology*, 12(1).
 25. Shimomura, Y., Kikuchi, Y., Suzuki, T., Uchida, H., Mimura, M. and Takeuchi, H., 2021. Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: a systematic review of the guidelines and algorithms. *Schizophrenia Research*, 236, pp.142-155.
 26. Singh, S., Khanna, D. and Kalra, S., 2020. Role of neurochemicals in schizophrenia. *Current Psychopharmacology*, 9(2), pp.144-161.
 27. Teleanu, R.I., Niculescu, A.G., Roza, E., Vladăncenco, O., Grumezescu, A.M. and Teleanu, D.M., 2022. Neurotransmitters—key factors in neurological and neurodegenerative disorders of the central nervous system. *International journal of molecular sciences*, 23(11), p.5954.
 28. Teleanu, R.I., Niculescu, A.G., Roza, E., Vladăncenco, O., Grumezescu, A.M. and Teleanu, D.M., 2022. Neurotransmitters—key factors in neurological and neurodegenerative disorders of the central nervous system. *International journal of molecular sciences*, 23(11), p.5954.
 29. Torrisi, S.A., Laudani, S., Contarini, G., De Luca, A., Geraci, F., Managò, F., Papaleo, F., Salomone, S., Drago, F. and Leggio, G.M., 2020. Dopamine, cognitive impairments and second-generation antipsychotics: from mechanistic advances to more personalized treatments. *Pharmaceuticals*, 13(11), p.365.
 30. Wiśłowska-Stanek, A., Kołosowska, K. and Maciejak, P., 2021. Neurobiological basis of increased risk for suicidal behaviour. *Cells*, 10(10), p.2519.



INTERNATIONAL
STANDARD
SERIAL
NUMBER
INDIA



INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

 9940 572 462  6381 907 438  ijirset@gmail.com



www.ijirset.com

Scan to save the contact details